D101 EFFICACY OF LIGELIZUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH OMALIZUMAB

In the Phase 2b core study, ligelizumab, a next generation high-affinity humanized monoclonal anti-IgE antibody, was effective in patients with chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines. This analysis evaluates the response to ligelizumab, during the Phase 2b extension study, in patients who did not achieve complete urticaria control with omalizumab in the core study.